)| PMID |
16380619 ( ) |
|---|---|
| Title | Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? |
| Abstract | Abnormal levels of interleukin (IL)-6 were described in patients with ALS, related to an inflammatory process. The authors compared IL-6 and tumor necrosis factor alpha (TNF-alpha) levels in CSF and sera from 10 hypoxemics and 10 normoxemics patients with ALS to those of 10 hypoxemics and 10 normoxemics neurologic controls. The same pattern exists in patients with ALS and controls: the highest levels are found in hypoxic conditions and undetectable levels are found in normoxemic conditions. Elevated IL-6 levels in ALS could correspond to a normal response to hypoxemia. Hospital, Lille, France. |
NOTE: Color highlight is limited to the abstract and SciMiner text-mining mode. If you see much more identified targets below from "Targets by SciMiner Summary" and "Targets by SciMiner Full list", they may have been identified from the full text.
Targets by SciMiner Summary
| HUGO ID | Symbol | Target Name | #Occur | ActualStr |
|---|---|---|---|---|
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | 51 | IL-6 | il 6 | interleukin 6 | |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | 40 | tumor necrosis factor alpha | TNF-alpha | tnf alpha | |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | 22 | ALS | SOD | |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | 11 | COX-2 | cox 2 | |
| 12680 | VEGFA | vascular endothelial growth factor A | 6 | VEGF | vascular endothelial growth factor | |
| 3796 | FOS | v-fos FBJ murine osteosarcoma viral oncogene homolog | 2 | ap 1 | AP-1 | |
| 11205 | SP1 | Sp1 transcription factor | 1 | SP-1 | |
Targets by SciMiner Full list
| HUGO ID | Symbol | Name | ActualStr | Score | FlankingText |
|---|---|---|---|---|---|
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | of interleukin (IL)-6 IL -6 were described in patients with ALS related to an inflammatory process |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | The authors compared IL-6 and tumor necrosis factor alpha TNF-alpha levels in CSF and |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | The authors compared IL-6 and tumor necrosis factor alpha TNF-alpha levels in CSF and sera from 10 hypoxemics and 10 |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | and sera from 10 hypoxemics and 10 normoxemics patients with ALS to those of 10 hypoxemics and 10 normoxemics neurologic controls |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | The same pattern exists in patients with ALS and controls the highest levels are found in hypoxic conditions |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | Elevated IL-6 levels in ALS could correspond to a normal response to |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | Elevated IL-6 levels in ALS could correspond to a normal response to hypoxemia |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | microglia was demonstrated in the spinal cord of patients with ALS |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | An excessive production of tumor necrosis factor alpha TNF-alpha with lower CSF levels of interleukin (IL)-6 IL -6 was |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD | 0.5 | levels of interleukin (IL)-6 IL -6 was demonstrated in a SOD 1 mouse model suggesting an increase cytotoxic potential of microglia |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | TNF-alpha could act as a principal driver for neuroinflammation because its |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | phases of the disease while several costimulating cytokines (IL-1_amp_#223;, IL-1_amp_#223 IL-6 and chemokines act to potentiate its effects |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | However there were conflicting results either no difference in IL-6 TNF-alpha or IL-12 was found in patients with ALS and |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | However there were conflicting results either no difference in IL-6 TNF-alpha or IL-12 was found in patients with ALS and healthy |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | in IL-6 TNF-alpha or IL-12 was found in patients with ALS and healthy and inflammatory controls or elevated levels of IL-6 |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | ALS and healthy and inflammatory controls or elevated levels of IL-6 and IL-1_amp_#223 in the CSF spinal cords and sera of |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | in the CSF spinal cords and sera of patients with ALS |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | Increased IL-6 levels were shown in pulmonary conditions such as obstructive sleep |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | role of hypoxemia in the regulation of cytokines by studying TNF-alpha and IL-6 in the sera and CSF of hypoxemic and |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | hypoxemia in the regulation of cytokines by studying TNF-alpha and IL-6 in the sera and CSF of hypoxemic and normoxemic patients |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | the sera and CSF of hypoxemic and normoxemic patients with ALS and neurologic controls |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | Plasma and CSF from patients with ALS and control subjects were obtained with informed consent as part |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | IL-6 and TNF-alpha levels in CSF and sera were determined using |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | IL-6 and TNF-alpha levels in CSF and sera were determined using a chemiluminescent |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | We found higher levels of IL-6 in CSF ( z = -2.7 p = 0.02 in |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | in serum ( z = -2.1 p = 0.04 and TNF-alpha in serum ( z = -2.5 p = 0.01 in |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | -2.5 p = 0.01 in hypoxemic vs normoxemic patients with ALS ( figure 1 |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | A correlation exists between Pao 2 and levels of CSF IL-6 ( p = 0.0001 r = -0.7 serum IL-6 ( |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | CSF IL-6 ( p = 0.0001 r = -0.7 serum IL-6 ( p = 0.007 r = -0.6 serum TNF-alpha ( |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | serum IL-6 ( p = 0.007 r = -0.6 serum TNF-alpha ( p = 0.001 r = -0.7 in patients with |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | ( p = 0.001 r = -0.7 in patients with ALS |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | In neurologic controls we found higher levels of IL-6 in CSF ( z = -2.8 p = 0.02 in |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | in serum ( z = -2.3 p = 0.02 and TNF-alpha in serum ( z = -2.0 p = 0.05 in |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | There were correlations between Pao 2 and CSF IL-6 ( p = 0.01 r = 0.5 serum IL-6 ( |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | CSF IL-6 ( p = 0.01 r = 0.5 serum IL-6 ( p = 0.01 r = 0.5 and serum TNF-alpha |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | IL-6 ( p = 0.01 r = 0.5 and serum TNF-alpha levels ( p = 0.01 r = 0.5 in neurologic |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | TNF-alpha was undetectable in CSF |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | We found no correlation between IL-6 or TNF-alpha levels in plasma and those in CSF |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | We found no correlation between IL-6 or TNF-alpha levels in plasma and those in CSF |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | IL-6 and TNF-alpha levels did not correlate with age clinical presentation |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | IL-6 and TNF-alpha levels did not correlate with age clinical presentation or disease |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | We found an increase in IL-6 levels in CSF and sera and TNF-alpha in sera in |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | an increase in IL-6 levels in CSF and sera and TNF-alpha in sera in hypoxemic patients with ALS and hypoxemic neurologic |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | and sera and TNF-alpha in sera in hypoxemic patients with ALS and hypoxemic neurologic controls vs normoxemic ones but no difference |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | controls vs normoxemic ones but no difference between patients with ALS and controls |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | A correlation existed between IL-6 levels and the severity of hypoxemia in both groups suggesting |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.3 | and growth factors such as vascular endothelial growth factor (VEGF) VEGF thought to play a role in the pathophysiology of sporadic |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | thought to play a role in the pathophysiology of sporadic ALS |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.3 | Expression of the VEGF gene is mainly stimulated by hypoxia through the binding of |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.3 | In CNS VEGF is mostly synthesized by endothelial cells and microglia |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | the other hand hypoxia stimulates the proinflammatory cytokines such as TNF-alpha and IL-6 mediated by others transcriptional factors nuclear factor-kappaB AP-1 |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | hand hypoxia stimulates the proinflammatory cytokines such as TNF-alpha and IL-6 mediated by others transcriptional factors nuclear factor-kappaB AP-1 and SP-1 |
| 3796 | FOS | v-fos FBJ murine osteosarcoma viral oncogene homolog | AP-1 | 1.0 | TNF-alpha and IL-6 mediated by others transcriptional factors nuclear factor-kappaB AP-1 and SP-1 |
| 11205 | SP1 | Sp1 transcription factor | SP-1 | 0.1 | IL-6 mediated by others transcriptional factors nuclear factor-kappaB AP-1 and SP-1 |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | excitatory amino acid nitric oxide and proinflammatory cytokines such as IL-6 TNF-alpha and IL-1_amp_#223 |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | amino acid nitric oxide and proinflammatory cytokines such as IL-6 TNF-alpha and IL-1_amp_#223 |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | Higher IL-6 and TNF-alpha levels could therefore correspond to a normal response |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | Higher IL-6 and TNF-alpha levels could therefore correspond to a normal response to hypoxemia |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | It was demonstrated that the upregulation of IL-6 induced by hypoxemia could represent an endogenous neuroprotective mechanism against |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | A neuroprotective effect of increased levels of IL-6 was also observed in animal models of ALS or in |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | levels of IL-6 was also observed in animal models of ALS or in the context of excitotoxicity after hypoxemia |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | COX-2 | 1.0 | mediator and a major downstream product of cyclooxygenase 2 (COX-2) COX-2 |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | COX-2 | 1.0 | Increased levels of PGE-2 and COX-2 were described in patients with ALS |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | levels of PGE-2 and COX-2 were described in patients with ALS |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | COX-2 | 1.0 | PGE-2 and COX-2 presented both angiogenic properties and reciprocal interactions between COX-2/PGE-2 COX-2 |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | COX-2 | 1.0 | COX-2 presented both angiogenic properties and reciprocal interactions between COX-2/PGE-2 COX-2 PGE-2 and VEGF are described |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.3 | angiogenic properties and reciprocal interactions between COX-2/PGE-2 COX-2 PGE-2 and VEGF are described |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | Our findings suggest that increased levels of IL-6 TNF-alpha PGE-2 and COX-2 observed in patients with ALS parallel |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | TNF-alpha | 1.7 | Our findings suggest that increased levels of IL-6 TNF-alpha PGE-2 and COX-2 observed in patients with ALS parallel motor |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | COX-2 | 1.0 | findings suggest that increased levels of IL-6 TNF-alpha PGE-2 and COX-2 observed in patients with ALS parallel motor neuronal loss and |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | of IL-6 TNF-alpha PGE-2 and COX-2 observed in patients with ALS parallel motor neuronal loss and could correspond to a natural |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | COX-2 | 1.0 | We hypothesize that COX-2 inhibitors may even be harmful in patients with ALS because |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | that COX-2 inhibitors may even be harmful in patients with ALS because they can block the natural upregulation loop of VEGF |
| 12680 | VEGFA | vascular endothelial growth factor A | VEGF | 3.3 | ALS because they can block the natural upregulation loop of VEGF during hypoxemia |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | Rapidly progressive restrictive respiratory failure with chronic hypoxemia occurs in ALS |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | IL-6 | 1.3 | This may explain the age-associated increase in IL-6 sera levels found after exercise in patients with neuromuscular diseases |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | levels found after exercise in patients with neuromuscular diseases including ALS |
| 11179 | SOD1 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | ALS | 0.5 | and tumor necrosis factor alpha sera levels in patients with ALS according to the condition of hypoxemia or normoxemia (Pao Pao |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | abnormal levels of interleukin il 6 were described in patients with als related to an inflammatory process. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | the authors compared il 6 and tumor necrosis factor alpha tnf alpha levels in csf and sera from 10 hypoxemics and 10 normoxemics patients with als to those of 10 hypoxemics and 10 normoxemics neurologic controls. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tumor necrosis factor alpha | 1.0 | the authors compared il 6 and tumor necrosis factor alpha tnf alpha levels in csf and sera from 10 hypoxemics and 10 normoxemics patients with als to those of 10 hypoxemics and 10 normoxemics neurologic controls. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | the authors compared il 6 and tumor necrosis factor alpha tnf alpha levels in csf and sera from 10 hypoxemics and 10 normoxemics patients with als to those of 10 hypoxemics and 10 normoxemics neurologic controls. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | elevated il 6 levels in als could correspond to a normal response to hypoxemia. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | an excessive production of tumor necrosis factor alpha tnf alpha with lower csf levels of interleukin il 6 was demonstrated in a sod 1 mouse model suggesting an increase cytotoxic potential of microglia. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tumor necrosis factor alpha | 1.0 | an excessive production of tumor necrosis factor alpha tnf alpha with lower csf levels of interleukin il 6 was demonstrated in a sod 1 mouse model suggesting an increase cytotoxic potential of microglia. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | an excessive production of tumor necrosis factor alpha tnf alpha with lower csf levels of interleukin il 6 was demonstrated in a sod 1 mouse model suggesting an increase cytotoxic potential of microglia. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | tnf alpha could act as a principal driver for neuroinflammation because its receptors are elevated in the presymptomatic phases of the disease while several costimulating cytokines il 1_amp_#223; il 6 and chem |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | tnf alpha could act as a principal driver for neuroinflammation because its receptors are elevated in the presymptomatic phases of the disease while several costimulating cytokines il 1_amp_#223; il 6 and chemokines act to potentiate its effects. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | however there were conflicting results: either no difference in il 6 tnf alpha or il 12 was found in patients with als and healthy and inflammatory controls or elevated levels of il 6 and il 1_amp_#223; in the csf spinal cords and sera of patients with als. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | however there were conflicting results: either no difference in il 6 tnf alpha or il 12 was found in patients with als and healthy and inflammatory controls or elevated levels of il 6 and il 1_amp_#223; in the csf spinal cords and sera of patients with als. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | increased il 6 levels were shown in pulmonary conditions such as obstructive sleep apnea in which paroxystic nocturnal desaturations lead to chronic hypoxemia. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | in light of the inflammatory hypothesis we investigated the role of hypoxemia in the regulation of cytokines by studying tnf alpha and il 6 in the sera and csf of hypoxemic and normoxemic patients with als and neurologic controls. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | in light of the inflammatory hypothesis we investigated the role of hypoxemia in the regulation of cytokines by studying tnf alpha and il 6 in the sera and csf of hypoxemic and normoxemic patients with als and neurologic controls. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | il 6 and tnf alpha levels in csf and sera were determined using a chemiluminescent assay quantiglo r_amp_d systems and an elisa test quantikine r_amp_d systems . |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | il 6 and tnf alpha levels in csf and sera were determined using a chemiluminescent assay quantiglo r_amp_d systems and an elisa test quantikine r_amp_d systems . |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | we found higher levels of il 6 in csf z = 2.7; p = 0.02 in serum z = 2.1; p = 0.04 and tnf alpha in serum z = 2.5; p = 0.01 in hypoxemic vs normoxemic patients with als figure 1 . |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | we found higher levels of il 6 in csf z = 2.7; p = 0.02 in serum z = 2.1; p = 0.04 and tnf alpha in serum z = 2.5; p = 0.01 in hypoxemic vs normoxemic patients with als figure 1 . |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | a correlation exists between pao 2 and levels of csf il 6 p = 0.0001 r = 0.7 serum il 6 p = 0.007 r = 0.6 serum tnf alpha p = 0.001 r = 0.7 in patients with als. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | a correlation exists between pao 2 and levels of csf il 6 p = 0.0001 r = 0.7 serum il 6 p = 0.007 r = 0.6 serum tnf alpha p = 0.001 r = 0.7 in patients with als. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | in neurologic controls we found higher levels of il 6 in csf z = 2.8; p = 0.02 in serum z = 2.3; p = 0.02 and tnf alpha in serum z = 2.0; p = 0.05 in hypoxemic controls vs normoxemic ones figure 2 . |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | in neurologic controls we found higher levels of il 6 in csf z = 2.8; p = 0.02 in serum z = 2.3; p = 0.02 and tnf alpha in serum z = 2.0; p = 0.05 in hypoxemic controls vs normoxemic ones figure 2 . |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | there were correlations between pao 2 and csf il 6 p = 0.01 r = 0.5 serum il 6 p = 0.01 r = 0.5 and serum tnf alpha levels p = 0.01 r = 0.5 in neurologic controls. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | there were correlations between pao 2 and csf il 6 p = 0.01 r = 0.5 serum il 6 p = 0.01 r = 0.5 and serum tnf alpha levels p = 0.01 r = 0.5 in neurologic controls. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | tnf alpha was undetectable in csf. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | we found no correlation between il 6 or tnf alpha levels in plasma and those in csf. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | we found no correlation between il 6 or tnf alpha levels in plasma and those in csf. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | il 6 and tnf alpha levels did not correlate with age clinical presentation or disease duration. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | il 6 and tnf alpha levels did not correlate with age clinical presentation or disease duration. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | we found an increase in il 6 levels in csf and sera and tnf alpha in sera in hypoxemic patients with als and hypoxemic neurologic controls vs normoxemic ones but no difference between patients with als and controls. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | we found an increase in il 6 levels in csf and sera and tnf alpha in sera in hypoxemic patients with als and hypoxemic neurologic controls vs normoxemic ones but no difference between patients with als and controls. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | a correlation existed between il 6 levels and the severity of hypoxemia in both groups suggesting that cytokine levels must be interpreted according to the degree of hypoxemia. |
| 12680 | VEGFA | vascular endothelial growth factor A | vascular endothelial growth factor | 1.0 | hypoxia activates the endothelial cells to release inflammatory mediators and growth factors such as vascular endothelial growth factor vegf thought to play a role in the pathophysiology of sporadic als. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | on the other hand hypoxia stimulates the proinflammatory cytokines such as tnf alpha and il 6 mediated by others transcriptional factors: nuclear factor kappab ap 1 and sp 1. |
| 3796 | FOS | v-fos FBJ murine osteosarcoma viral oncogene homolog | ap 1 | 1.0 | on the other hand hypoxia stimulates the proinflammatory cytokines such as tnf alpha and il 6 mediated by others transcriptional factors: nuclear factor kappab ap 1 and sp 1. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | on the other hand hypoxia stimulates the proinflammatory cytokines such as tnf alpha and il 6 mediated by others transcriptional factors: nuclear factor kappab ap 1 and sp 1. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | hypoxemia episodes cause early microglia activation followed by the release of a variety of neurotoxic products including excitatory amino acid nitric oxide and proinflammatory cytokines such as il 6 tnf alpha and il 1_amp_#223;. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | cute hypoxemia episodes cause early microglia activation followed by the release of a variety of neurotoxic products including excitatory amino acid nitric oxide and proinflammatory cytokines such as il 6 tnf alpha and il 1_amp_#223;. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | higher il 6 and tnf alpha levels could therefore correspond to a normal response to hypoxemia probably via nf kappab. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | higher il 6 and tnf alpha levels could therefore correspond to a normal response to hypoxemia probably via nf kappab. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | it was demonstrated that the upregulation of il 6 induced by hypoxemia could represent an endogenous neuroprotective mechanism against excitotoxic factor injury. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | a neuroprotective effect of increased levels of il 6 was also observed in animal models of als or in the context of excitotoxicity after hypoxemia. |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | cox 2 | 1.0 | the same observation was made for prostaglandin e 2 pge 2 which is an inflammatory mediator and a major downstream product of cyclooxygenase 2 cox 2 . |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | cox 2 | 1.0 | increased levels of pge 2 and cox 2 were described in patients with als. |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | cox 2 | 1.0 | pge 2 and cox 2 presented both angiogenic properties and reciprocal interactions between cox 2/pge 2 and vegf are described. |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | cox 2 | 1.0 | our findings suggest that increased levels of il 6 tnf alpha pge 2. and cox 2 observed in patients with als parallel motor neuronal loss and could correspond to a natural response to hypoxemia. |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tnf alpha | 1.0 | our findings suggest that increased levels of il 6 tnf alpha pge 2. and cox 2 observed in patients with als parallel motor neuronal loss and could correspond to a natural response to hypoxemia. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | our findings suggest that increased levels of il 6 tnf alpha pge 2. and cox 2 observed in patients with als parallel motor neuronal loss and could correspond to a natural response to hypoxemia. |
| 9605 | PTGS2 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | cox 2 | 1.0 | we hypothesize that cox 2 inhibitors may even be harmful in patients with als because they can block the natural upregulation loop of vegf during hypoxemia. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | il 6 | 1.0 | this may explain the age associated increase in il 6 sera levels found after exercise in patients with neuromuscular diseases including als. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | interleukin 6 | 1.0 | csf and sera interleukin 6 levels and tumor necrosis factor alpha sera levels in patients with als according to the condition of hypoxemia or normoxemia pao 2 . *significant difference p _lt_ 0.05 between the hypoxemic and the |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tumor necrosis factor alpha | 1.0 | csf and sera interleukin 6 levels and tumor necrosis factor alpha sera levels in patients with als according to the condition of hypoxemia or normoxemia pao 2 . *significant difference p _lt_ 0.05 between the hypoxemic and the normoxemic groups. |
| 6018 | IL6 | interleukin 6 (interferon, beta 2) | interleukin 6 | 1.0 | csf and sera interleukin 6 levels and tumor necrosis factor alpha sera levels in neurologic controls according to the condition of hypoxemia or normoxemia pao 2 . *significant difference p _lt_ 0.05 between the hypoxemic and t |
| 11892 | TNF | tumor necrosis factor (TNF superfamily, member 2) | tumor necrosis factor alpha | 1.0 | csf and sera interleukin 6 levels and tumor necrosis factor alpha sera levels in neurologic controls according to the condition of hypoxemia or normoxemia pao 2 . *significant difference p _lt_ 0.05 between the hypoxemic and the normoxemic groups. |